Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases

Journal of Magnetic Resonance Imaging

Volumn 40, Issue 1, 2014, Pages 113-118

  Bashir, Mustafa R ^a   Mody, Rekha ^b   Neville, Amy ^a   Javan, Ramin ^a   Seaman, Danielle ^a   Kim, Charles Y ^a   Gupta, Rajan T ^a   Jaffe, Tracy A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

deep vein thrombosis; DVT; ferumoxytol; SPIO

Indexed keywords

CONTRAST MEDIUM; FERUMOXYTOL; GADOFOSVESET; GADOLINIUM; IRON; IRON DERIVATIVE; MAGNETITE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; DEEP VEIN THROMBOSIS; END STAGE RENAL DISEASE; FEMALE; HUMAN; IMAGE QUALITY; LEG VEIN; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; MUSCLE; PHLEBOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; SCORING SYSTEM; VERY ELDERLY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIAGNOSTIC USE; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; PHLEBOGRAPHY; RENAL ARTERY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84902366242     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24330     Document Type: Article

References (25)

1. Gaitini D,. Multimodality imaging of the peripheral venous system. Int J Biomed Imaging 2007:54616; DOI:10.1155/2007/54616.
2. Cushman M,. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44: 62-69.
3. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
4. Kroegel C, Reissig A,. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70: 7-30.
5. Enden T, Storas TH, Negard A, et al. Visualization of deep veins and detection of deep vein thrombosis (DVT) with balanced turbo field echo (b-TFE) and contrast-enhanced T1 fast field echo (CE-FFE) using a blood pool agent (BPA). J Magn Reson Imaging 2010; 31: 416-424.
6. Hadizadeh DR, Kukuk GM, Fahlenkamp UL, et al. Simultaneous MR arteriography and venography with blood pool contrast agent detects deep venous thrombosis in suspected arterial disease. AJR Am J Roentgenol 2012; 198: 1188-1195.
7. Huang SY, Kim CY, Miller MJ, et al. Abdominopelvic and lower extremity deep venous thrombosis: evaluation with contrast-enhanced magnetic resonance venography with a blood pool agent. Am J Roentgenol 2013; 201: 208-214.
8. Goyen M,. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008; 4: 1-9.
9. Schneider G, Pasowicz M, Vymazal J, et al. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol 2010; 195: 476-485.
10. Pfeil A, Betge S, Poehlmann G, et al. Magnetic resonance VIBE venography using the blood pool contrast agent gadofosveset trisodium-an interrater reliability study. Eur J Radiol 2012; 81: 547-552.
11. Rydahl C, Thomsen HS, Marckmann P,. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-144.
12. Cohan RH, Davenport MS, Dillman JR, et al. ACR Manual on Contrast Media v8. 2012. American College of Radiology, Reston, VA.
13. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE,. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
14. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605.
15. Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ,. Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation 2013; 96: 91-96.
16. Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 2005; 21: 46-52.
17. Harisinghani M, Ross RW, Guimaraes AR, Weissleder R,. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia 2007; 9: 1160-1165.
18. Hamilton BE, Nesbit GM, Dosa E, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011; 197: 981-988.
19. Storey P, Lim RP, Chandarana H, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 2012; 47: 717-724.
20. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
21. Li W, Salanitri J, Tutton S, et al. Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism-preliminary experience. Radiology 2007; 242: 873-881.
22. Neuwelt EA, Hamilton BE, Varallyay CG, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009; 75: 465-474.
23. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31: 440-446.
24. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC,. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009; 253: 689-696.
25. Westerbeek RE, Van Rooden CJ, Tan M, et al. Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg. J Thromb Haemost 2008; 6: 1087-1092.